The receptor tyrosine kinase c-Met is the cellsurface receptor for hepatocyte growth factor (1, 2) . While c-Met plays normal roles in stem and progenitor cells, abnormal activity of c-Met resulting from overexpression, inappropriate ligand binding or mutation is implicated in tumor growth, invasion and metastasis (1, 2) . Numerous preclinical studies with animal models support the notion that inhibition of c-Met provides a therapeutic approach to cancer treatment, and several biologic and small-molecule agents are in clinical evaluation in humans (3) .
The crystal structure of the unphosphorylated c-Met kinase domain has the canonical bilobal kinase fold typical of protein kinases (4) . The unphosphorylated kinase domain adopts an autoinhibited conformation that is mediated largely by the activation loop, which is ordered and folds against active site features of the kinase (4) . In particular, the ordered activation loop conformation obstructs access to the active site and places helix αC, and conserved catalytic residues that depend on the orientation of helix αC, in an inactive conformation (4) .
Activation of c-Met begins with the binding of hepatocyte growth factor to the extracellular receptor domain of c-Met, which results in c-Met oligomerization and autophosphorylation of the kinase domain at Y1234 and Y1235 (1, 2) . The structural basis of activation to date is limited to crystallographic studies of phosphorylationmimetic mutants. This approach is exemplified by a triple mutant containing an activation-loop mutation (Y1235D) present in certain carcinomas (5) and Y1194F and Y1234F mutations that were introduced to obtain homogenous unphosphorylated enzyme (6) . In contrast to the fully-ordered activation loop of the unphosphorylated enzyme (4), residues 1231-1244 of the activation loop of the putative phosphorylation-mimetic mutant Y1235D are disordered (6) . One feature of activated kinases is the reorientation of helix αC that contributes to the formation of a viable active site (7) . However, the Y1199-Y1234F-Y1235D mutant crystallized with helix αC in the inactive conformation (6) . In addition, the Y1235D single-point mutant has a reduced k cat compared to the activated, autophosphorylated wild-type enzyme (8) . It appears that the Y1235D activating mutant does not replicate the biologically relevant activation mechanism of c-Met autophosphorylation.
The clinical candidate MK-2461 is a novel, receptor tyrosine kinase inhibitor (3, 9) . MK-2461 preferentially binds the phosphorylated c-Met kinase domain in vitro and preferentially inhibits phosphorylated c-Met in cancer cell lines (9) . MK-2461 also inhibits the kinases Flt1 and Ron with similar potency to c-Met but other kinases are 8-30 fold less sensitive to MK-2461 (9) . The success of targeting kinases that are abnormally activated in disease (10) generates interest in understanding the structural basis of activated kinase inhibition exhibited by compounds such as MK-2461.
Here we present the structural basis of preferential inhibition of activated c-Met. First, the origins of c-Met kinase domain activation are revealed by the crystal structure of the kinase domain in the bona fide and biologically relevant autophosphorylated state. The structure differs from those previously observed with activating mutations.
Second, the structural basis of selective inhibition of the dually phosphorylated kinase domain is revealed by the crystal structure of autophosphorylated c-Met in complex with an MK-2461 analog that is 20-fold selective for the dually phosphorylated state. Taken together, the results provide a framework for the rational design of inhibitors that target the activated state of c-Met.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification-A PCR product encoding residues 1048-1348 of human cMet with a C-terminal His-tag was amplified from partial c-Met cDNA (Open Biosystems LifeSeq3489592) and cloned via Gateway cloning method into a custom destination vector designed for baculovirus recombination derived from the transfer vector pVL1393 (Pharmingen, San Diego, CA) (11) .
The generation of recombinant baculovirus using BacMagic (Novagen) was performed according to the manufacturer's procedures.
Virus harboring the c-Met kinase domain was used to infect Sf21 insect cells at an MOI of 0.2. The cells were grown at 27 ˚C and harvested 72 h post infection.
Cells were lysed by microfluidization in 50 mM Tris, pH 8.0, 250 mM NaCl, 5 mM 2-mercaptoethanol, 25 mM imidazole, and 5% glycerol. The soluble lysate fraction was loaded on to a HisTrap FF crude column in 50 mM Tris, pH 8.0, 150 mM NaCl, 5 mM 2-mercaptoethanol, and 25 mM imidazole and the enzyme eluted with a gradient of 50-500 mM imidazole. The enzyme was loaded on to QSepharose in 50 mM Tris, pH 8.5, 50 mM NaCl and the flowthrough loaded onto heparinSepharose in 50 mM HEPES, pH 7.0, 50 mM NaCl, followed by elution with a gradient to 1 M NaCl. Final purification was with gel filtration with a Superdex 75 column equilibrated in 50 mM Tris, pH 8.0, 150 mM NaCl. The purified enzyme was exchanged via desalting column into crystallization buffer (50 mM HEPES, pH 7.0, 250 mM NaCl, 3 mM DTT, 5% glycerol) prior to concentration for crystallography.
Autophosphorylated enzyme was generated by incubation in 50 mM Tris, pH 8.0, 150 mM NaCl, 5 mM MgCl 2 and 1 mM ATP at 4 ˚C for 30 min. A mass increase of 160 Da was verified by LCMS, the reaction quenched with 10 mM EDTA, and the enzyme was exchanged into crystallization buffer as above.
Calorimetry-ITC was performed at 25 ˚C with an ITC200 (GE Healthcare) by injecting 2 μl of 300 μM compound 1 in 50 mM HEPES, pH 7.0, 250 mM NaCl, 3 mM DTT, 5% glycerol, and 1% DMSO into 40 μM c-Met kinase domain in the same buffer. The injection time was 4 s and the injection delay was 180 s. Data were fit with nonlinear least-squares to a single-site binding model with Origin for ITC v6.0 (MicroCal) by varying stoichiometry, ΔH, and the association constant (K a ).
Activity assays-Inhibition of peptide phosphorylation was carried out as described elsewhere (9) Reactions were initiated by addition of 250 μM ATP, incubated at 37 ˚C for 3 h, and quenched with EDTA (10 mM final concentration). Samples were analyzed by LCMS on a Thermo LTQ MS, using a Varian PLRP-S column and a gradient from 18-63% acetonitrile containing 0.01% trifluroacetic acid over 10 min to separate the c-Met kinase domain from BSA. Spectra were analyzed with Promass (Novatia) to deconvolute and assign peak intensities to the singly phosphorylated (+80 Da) and unphosphorylated forms of the protein.
Crystallization-Crystals were obtained using 15.6 mg/ml autophosphorylated c-Met kinase domain mixed at a 1:1 ratio with the reservoir solution (150 mM malic acid, 20% PEG 3350, pH 7.0). Crystals were grown at 20 ˚C as sitting drops using microseeding and cryo-protected with 20% ethylene glycol. Crystals of the autophosphorylated c-Met kinase domain in complex with compound 1 were obtained by cocrystallization under the same conditions of 15.6 mg/mL enzyme in the presence of a 2-fold molar excess of compound 1.
Structure Determination-Data were collected at the IMCA beamline (Advanced Photon Source, Argonne National Labs) using an X-ray wavelength of 1.00 Å. Oscillation frames of 0.5 degrees were collected over a total rotation range of 180 degrees using an ADSC Quantum 210 detector. Data were integrated and reduced with HKL2000 (12) . Structures were determined by molecular replacement using the structure of the cMet kinase domain in complex with K252a (PDB code 1R1W) as a starting model for rigid body refinement with REFMAC as implemented in CCP4 (13) . The model was rebuilt manually with Coot (14) and completed using iterative rounds of refinement with autoBUSTER version 1.7.3 (Global Phasing Limited) and rebuilding. SigmaA-weighted (15) Compound 1 also exhibits a preference for the autophosphorylated state in functional assays. In a fluorescence assay that measures inhibition of the autophosphorylated kinase domain activity with a peptide substrate, compound 1 exhibits an IC 50 of 11±5 nM (Fig. 1B) . In a LCMS assay that directly measures autophosphorylation of the kinase domain to the singly phosphorylated state, compound 1 exhibits an IC 50 of 1.7±0.3 μM (Fig.  1C) The staurosporine analog K252a is a c-Met inhibitor (18) . In the same assays as used for compound 1, K252a exhibits IC 50 values of 113±12 nM for peptide phosphorylation by dually phosphorylated c-Met (Fig. 1B) and 81±9 nM for autophosphorylation (Fig. 1C) . The results for K252a suggest that the different values observed for compound 1 do not reflect assay methodology but do reflect the combined properties of compound 1 and the enzyme phosphorylation state.
RESULTS
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Structure of the Autophosphorylated c-Met
Kinase Domain-The 1.6 Å crystal structure of the human c-Met kinase domain phosphorylated at Y1234 and Y1235 was determined to understand the structural basis of c-Met activation by phosphorylation and to provide the framework for understanding selective inhibition of the activated kinase domain (Table 1 ). The presence of dual phosphorylation was confirmed with mass spectrometry and by direct observation of the phosphate groups of pY1234 and pY1235 in the ligand-bound crystal structure (see below). The general structure of the C lobe is largely unchanged upon activation loop phosphorylation The activation loop of unphosphorylated cMet is folded onto the enzyme in an autoinhibitory conformation ( Fig. 2A) . In contrast, the structure of unliganded, autophosphorylated c-Met shows that the activation loop is ejected from the autoinhibitory conformation seen in the unphosphorylated structure (Fig. 2B) . Electron density for the activation loop between the DFG motif and L1245 is not visible in the structure suggesting that residues 1225-1244 of the activation loop are disordered following phosphorylation.
The ejection of the activation loop from the active site is accompanied by a marked reorientation of helix αC (Fig. 2B) . The movement of helix αC is similar to that observed in the structure of other activated protein kinases (7) , and leads to partial alignment of the side chains of E1127 and K1110 with the expected active conformation. However, the distance between the side chains (5.8 Å) is longer than would be expected for the conserved salt bridge typically observed in the fully activated conformation (7). The conserved catalytic base D1204 and Mg 2+ chelating residue N1209 of the catalytic loop move approximately 1.6 Å towards the active site upon phosphorylation.
The ejection of the activation loop also has marked structural consequences for the G loop, which is the Gly-rich loop that binds ATP. In the unphosphorylated structure (4), residues M1229-E1233 of the activation loop pack against the G loop placing it in a position that occludes the ATPbinding site (Fig. 3A) . Upon phosphorylation and ejection of the activation loop, the G loop adopts a remarkably different conformation that involves a movement of 9-11 Å for the C β atoms of R1086, H1088 and F1089 (Fig. 3A) . The extended β-hairpin conformation of the G loop is incompatible with the presence of the activation loop in the unphosphorylated state. This structural transition removes the active-site obstruction seen in the unphosphorylated structure by the G loop side chains of R1086, H1088 and H1089 and thus relieves an autoinhibitory feature of the unphosphorylated kinase. particularly for the G loop (see below). F1223 is in a similar DFG-in orientation to the unbound phosphorylated form, as seen for Type I kinase inhibitors (19) . The observed electron density allows unambiguous positioning of compound 1 in the structure (Fig. 4A) .
The tricyclic ring of compound 1 occupies the ATP binding site (Fig.  2C ) in a predominantly hydrophobic environment formed by I1084, V1092, A1108, K1110, L1140, Y1159, M1160, M1211 and A1221 (Fig. 4B) . The polar groups of the inhibitor make both direct and water-mediated hydrogen bonds with c-Met (Fig.  4C) . A direct hydrogen bond is formed between the amide NH of the inhibitor and the backbone carbonyl of R1086 (2.9 Å). The two carbonyl oxygens of compound 1 are coordinated, via a network of water-mediated hydrogen bonds, to the side chain and backbone amide nitrogen of D1164 (Fig. 4C) . D1164 also forms a bridging hydrogen bond via a water molecule with the inhibitor pyridine moiety. Density for the pyridine group was not as clearly defined as for the rest of compound 1. However, the electron density, geometric constraints, and chemical environment are consistent with the modeled orientation.
The G loop undergoes a conformational change upon binding compound 1 with the side chains of R1086, H1088 and F1089 experiencing movements of 6-20 Å to form a cap to the binding pocket of compound 1 (Fig. 3B) . The induced-fit conformational change of the G loop also introduces new intramolecular interactions within c-Met (Fig. 5) . F1089 of the G loop forms a new packing interaction with helix αC and K1110 and E1127 form a short salt bridge (2.8 Å). Also, the side chain of H1088 of the G loop forms a new hydrogen bond with the side chain of D1204 (2.5 Å).
One of the more striking differences observed between the unbound, phosphorylated c-Met structure and the structure observed in the presence of compound 1 is the nearly complete ordering of the activation loop, including the phosphate groups of pY1234 and pY1235 (Fig. 5) . Only a short region of the activation loop remains disordered (residues 1240-1243). Upon loop stabilization, the phosphotyrosine residues form electrostatic interactions; pY1234 interacts with K1232 and K1253, and pY1235 interacts with R1227 and H1238 (Fig. 5) .
DISCUSSION
Structural Basis of Activation by Autophosphorylation-The kinase activity of c-Met is stimulated by activation-loop autophosphorylation at Y1234 and Y1235 following c-Met dimerization upon binding hepatocyte growth factor (1, 2) .
In the unphosphorylated enzyme, the activation loop is folded against the active site to disrupt the catalytically competent conformation of the kinase domain and occlude the ATP binding site (4). The autoinhibitory features of c-Met are relieved by the ejection and disorder of the activation loop upon autophosphorylation. In particular, the ATP binding site becomes exposed when the G loop adopts the extended conformation and helix αC and the catalytic loop reorients to form a viable active site. The side chain of F1223 of the DFG motif is in the active DFG-in conformation in both the unphosphorylated and phosphorylated states. The change in helix αC orientation and the DFGin motif mirror those seen in other activated protein kinases (7) .
The ejection of the activation loop from the active site is most likely a consequence of the incompatibility of pY1234 and pY1235 with the autoinhibited conformation. In particular, Y1235 is buried in the unphosphorylated structure and forms a hydrogen bond with E1127 (4). It is likely that the activation loop rearrangement is driven by an unfavorable burial of the pY1235 phosphate (6) .
It is notable that the active conformation of helix αC is not present in the triple mutant structure that includes the activation-loop phosphorylation mimic Y1235D (6) .
Other structural studies of mutant c-Met kinase domains bound with inhibitors have also employed multiple mutations in the activation loop selected from single-point oncogenic mutations (20, 21) . In these cases, the activation loop is disordered, as seen here upon phosphorylation, and formally consistent with the use of naturally occurring activating mutations. However, helix αC in the mutant structures (6, 20, 21) does not adopt the active orientation seen here for autophosphorylated c-Met. In the case of the ligand-bound mutant structures (19, 20) , apo structures of the c-Met mutants have not been reported, so it is unknown if the inhibitor induces the inactive helix αC conformation or that the orientation of helix αC results from the presence of the multiple mutations. Nonetheless, it is clear that bona fide autophosphorylated c-Met adopts an active conformation that is not necessarily induced by activation-loop mutations.
Structural Basis of Selective Inhibition-The binding pose of compound 1 to the autophosphorylated kinase domain is incompatible with the presence of the autoinhibitory conformation of the activation loop of the unphosphorylated enzyme.
In particular, the extension of the G loop following activation loop ejection upon phosphorylation is required to permit access to the ATP-binding site occupied by compound 1 (Fig. 2A) . Moreover, the extended conformation of the G loop is primed in the dually phosphorylated state to bind compound 1. The ordering of the phosphorylated activation loop appears to be related to the conformational change of the G loop upon binding compound 1 and may reflect formation of a domino effect of interactions that originate with the G loop. The induced-fit movement of the G loop upon binding compound 1 allows H1088 at the top of the G loop to form a short (2.5 Å) hydrogen bond with D1204 (Fig. 5) . In turn, the H1088-D1204 pair forms packing interactions with L1225, which is disordered in the unphosphorylated state, and may nucleate stabilization of the loop. Upon activation loop stabilization, pY1234 and pY1235 form new electrostatic interactions (Fig. 5) . It is tempting to speculate that the G loop would adopt a similar conformation upon binding ATP to that induced by the occupation of the ATP-binding site by compound 1, leading to ordering of the phosphorylated activation loop that would then provide a scaffold for substrate recognition and binding.
The activation loops of protein kinases have been observed in both disordered conformations (as seen here for phosphorylated c-Met) and ordered conformations (as seen here for phosphorylated c-Met upon ligand binding). When viewed in isolation, the ordered activation loop of c-Met in the autophosphorylated, ligandbound state appears to lack a regular structure (Fig.  6 ). When compared with the ordered activation loops seen in the crystal structures of the phosphorylated tyrosine kinase domains of IRK and Lck (22, 23) , however, the phosphorylated activation loops of c-Met, IRK and Lck adopt a clearly conserved structural motif (Fig. 6) . The activation loops of Lck, c-Met and IRK contain one, two and three pTyr residues, respectively, and share a conserved pTyr (pTyr 1235 in c-Met) (Fig.  6) . The conserved pTyr in each kinase forms an electrostatic interaction with a conserved Arg (R1227 in c-Met) that forms the stapled base of the activation loop (Fig. 6) .
IRK and c-Met contain a second conserved pTyr residue (corresponding to pY1234 in c-Met; Fig. 6 ). The interactions involving pY1234 are not conserved as is the case for the R1227-pY1235 interaction. IRK contains a third pY at position 1158. Interestingly, Y1158 of IRK aligns in sequence with Y1230 of c-Met but with the side chains in a different orientation and with pY1158 making no contacts with the rest of IRK (Fig. 6) . It does not appear, therefore, that multiple phosphorylation of the activation loops of IRK and c-Met play a structural role in adopting the active conformation.
Thermodynamic Features of Selective Inhibition-Enthalpy drives binding of compound 1 to autophosphorylated c-Met whereas binding to the unphosphorylated state is more entropy driven. The enthalpy changes are consistent with activation loop ordering upon binding. This presumably contributes a favorable enthalpy term via the formation of new intramolecular interactions involving the activation loop including the ionic interactions with the phosphate groups as well as intermolecular bonding interactions with compound 1.
In contrast, binding to the unphosphorylated form would involve ejection of the activation loop from the nucleotide binding pocket leading to the loss or changes of intramolecular interactions of the activation loop in the unbound state. The absence of the phosphate group bonding network may also lead to a partial disorder of the activation loop, perhaps reflected in the difference in entropy changes upon binding to the two forms of c-Met.
Comparison with Other c-Met inhibitorsCompound 1 is a Type I inhibitor in which the cMet kinase domain adopts the active DFG-in conformation with helix αC in the active conformation. The Type I binding mode of compound 1 is clearly distinct from Type I modes seen for unambiguously unphosphorylated c-Met in which the activation loop is in the autoinhibitory conformation (24) (25) (26) (27) (28) . In these examples, crystal structures show that inhibitors form hydrogen bond interactions with the hinge region and π-stacking interactions with Y1230 of the activation loop. Such inhibitors are potentially specific for the unphosphorylated state given the ejection of the activation loop upon phosphorylation and are potentially sensitive to the Y1230H mutation observed in certain cancers. A different Type I inhibitor is exemplified by AM7 (29) .
In the crystal structure of putatively unphosphorylated c-Met bound to AM7, the activation loop is disordered and AM7 packs against helix αC, which is in the inactive conformation. The position of helix αC in the dually phosphorylated state is incompatible with the AM7 binding pose observed in the putative unphosphorylated state. Clearly, the ability of cMet to adopt different conformations, including induced-fit changes that may prove elusive to computational approaches, allows for a variety of inhibition modes that rely on the presence or absence of specific conformational features of both the activation and G loops.
Implications for Kinase Drug Design-The conserved nature of protein kinases introduces challenges to the discovery of selective inhibitors. Consequently small molecule inhibitors for one kinase typically exhibit activity towards other kinases when profiled across the kinome (30) .
The conformational plasticity of kinase domains can result in distinct conformations of a given kinase. In the case of c-Met, selective binding of compound 1 to the phosphorylated kinase domain depends on a large (up to 20 Å) induced-fit change of the G loop.
Moreover, the previously unobserved ordering of the phosphorylated activation loop of c-Met upon inhibitor binding contributes to favorable binding thermodynamics and presents an unprecedented c-Met scaffold for the rational design of selective c-Met inhibitors. Our results support the notion that kinase inhibitor specificity can arise from details of structural plasticity that can introduce additional threedimensional diversity to the overall kinase fold. 
FOOTNOTES
